Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart
  • Log out

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions

Linezolid to treat extensively drug-resistant TB: retrospective data are confirmed by experimental evidence

Giovanni Sotgiu, Rosella Centis, Lia D'Ambrosio, Antonio Spanevello, Giovanni Battista Migliori on behalf of the International Group for the study of Linezolid
European Respiratory Journal 2013 42: 288-290; DOI: 10.1183/09031936.00191712
Giovanni Sotgiu
1Epidemiology and Medical Statistics Unit, Dept of Biomedical Sciences, University of Sassari, Sassari
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rosella Centis
2World Health Organization Collaborating Centre for Tuberculosis and Lung Diseases, Fondazione S. Maugeri, Care and Research Institute, Tradate
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lia D'Ambrosio
2World Health Organization Collaborating Centre for Tuberculosis and Lung Diseases, Fondazione S. Maugeri, Care and Research Institute, Tradate
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Antonio Spanevello
3Università degli Studi dell'Insubria, Varese, and Fondazione S. Maugeri, Care and Research Institute, Tradate, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Giovanni Battista Migliori
2World Health Organization Collaborating Centre for Tuberculosis and Lung Diseases, Fondazione S. Maugeri, Care and Research Institute, Tradate
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: giovannibattista.migliori@fsm.it
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

To the Editor:

Extensively drug-resistant tuberculosis (XDR-TB) (defined as TB caused by Mycobacterium tuberculosis strains with in vitro resistance to isoniazid and rifampicin plus any fluoroquinolone and at least one of the second-line injectable drugs, amikacin, capreomycin or kanamycin) on top of being a growing public health concern, represents a nightmare for the clinician [1–4]. The crucial therapeutic issue is the difficulty of identifying at least four available “active” anti-TB drugs, to ensure treatment success as well as to prevent the emergence of additional drug resistance [1–4].

After more than 40 years without new anti-TB drugs appearing on the horizon, new chemical compounds (i.e. bedaquiline, PA-824 and delamanid) seem promising for these difficult-to-treat cases of TB [4, 5].

While the necessary experimental studies will prove how to use them, more and more interest is currently focused on existing antibacterial drugs with new indications for drug-resistant TB, particularly linezolid, meropenem, clofazimine and cotrimoxazole [6–9].

Based on in vitro and pharmacological data, suggesting that linezolid (an oxazolidinone antibiotic) could be efficacious in treating mycobacterial infections, and on anedoctal evidence of its effectiveness in the smallest groups of patients, it was used off-label, despite its high price, to treat multidrug-resistant (MDR) TB cases in several countries. The little scientific supporting data on the efficacy, safety and tolerability of linezolid came from ad hoc randomised, controlled clinical trials, as well as from large observational studies [7].

The European Respiratory Journal recently published a systematic review and a meta-analysis of individual patients focused on the main published epidemiological observational studies (n=12), describing cohorts of TB patients (n=121) treated with linezolid-containing regimens in 11 countries [7]. The selected papers had the following inclusion criteria: description of at least five culture- and drug-susceptibility testing confirmed MDR- or XDR-TB patients treated with linezolid-containing regimens; proportion of childhood patients less than 25% of the total sample; available evidence on efficacy, safety and tolerability.

Individual data were extracted from the manuscripts and collected in an ad hoc electronic form containing variables related to the efficacy, safety and tolerability profiles. The information retrieved was confirmed and/or updated, when possible, by the responsible authors of the selected papers. The guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) were followed.

A high proportion of MDR-TB cases achieved sputum smear (86 out of 93; 92.5%) and culture (100 out of 107; 93.5%) conversion after treatment with individualised linezolid-containing therapeutic schemes and 99 out of 121 (81.8%) achieved treatment success, with no differences in efficacy between those treated with a daily linezolid dosage ≤600 mg versus >600 mg.

Unfortunately, adverse events were observed in 58.9% (63 out of 107) of the cases (68.4% of them reported major adverse events); moreover, the frequency was significantly higher when the daily linezolid dose exceeded 600 mg.

More recently, a study by Lee et al. [10] provided, for the first time, the prospective experimental evidence needed on the efficacy, safety and tolerability of linezolid to treat XDR-TB.

Out of 39 XDR-TB, patients 87% showed a negative sputum culture after 6 months of treatment with linezolid-containing regimens. Linezolid (600 mg) was prescribed daily to the enrolled cohort at the beginning of the clinical trial; after 4 months of exposure to linezolid or after sputum smear conversion, a subgroup was administered a 300 mg daily dosage. Adverse events, potentially attributable to linezolid, occurred in 31 out of 38 (82%) patients, with a smaller proportion in those randomised to a 300 mg daily dosage (11 out of 16; 69%).

The aim of the present study was to analyse the safety, tolerability and efficacy of linezolid in the XDR-TB subgroup of the meta-analytic cohort [7] and to compare these results with those described by Lee et al. [10].

Statistical analyses were carried out using Stata 9.0 (StataCorp, College Station, TX, USA).

The XDR-TB patients enrolled in the meta-analysis were 39 out of 120 (32.5%) cases; most of them were male (24 out of 39; 61.5%), with a median (interquartile range) age of 36 (28–42) years. A daily dose of linezolid ≤600 mg and >600 mg were prescribed to 25 out of 39 (64.1%) and 14 out of 39 (35.9%) patients, respectively. The safety and tolerability profile is summarised in table 1.

View this table:
  • View inline
  • View popup
Table 1– Retrospective evaluation of the safety and tolerability of linezolid in 39 extensively drug-resistant tuberculosis cases

The proportion of adverse events in 34 XDR-TB patients was >60%, with 75% determining an interruption of treatment. After a median exposure to linezolid of 315 days, peripheral neuropathy was the most common adverse effect (55.2%), followed by anaemia (31.0%) and optic neuritis (20.0%). Although the proportion of adverse events was higher in the group of individuals treated with a linezolid daily dosage of ≤600 mg, the difference was not statistically significant.

The XDR-TB meta-analytic observational cohort [7] and the experimental group of Lee et al. [10] seem to be not statistically different in terms of proportions of adverse events attributable to linezolid prescribed at the daily dose of ≤600 mg (14 out of 20, 70% versus 31 out of 38, 82%; p=0.30), as well as of culture converters after 4 and 6 months of linezolid exposure (14 out of 25, 56% versus 15 out of 19, 79%; p=0.11; 18 out of 25, 72% versus 34 out of 38, 89%; p= 0.08, respectively).

On top of sharing the same conclusions (linezolid is effective but, due to adverse events, patients need careful monitoring), the rough statistical comparison between the two studies confirms that the dosage ≤600 mg·day−1 has the best risk–benefit profile [7, 10]. It has demonstrated an equal observational and experimental clinical efficacy in a difficult-to-treat group of TB patients, even if the limited sample size could represent a methodological shortcoming. More experimental evidence is urgently needed, preferably based on strong indicators, predictive of high efficacy, after a short period of drug exposure, following the example of randomised clinical trials on new anti-HIV and anti-hepatitis C drugs.

A growing amount of data from linezolid-exposed cohorts more and more clearly supports the rationale of prescribing the drug daily at a low dose, tailored to the pharmacokinetic profile obtained through therapeutic drug monitoring [7].

The identification of the adequate daily exposure to linezolid will prevent occurrence of adverse events, both life-threatening (e.g. determining the physician's decision to stop the drug) and non-serious (e.g. lowering the patient's motivation to continue the prescribed treatment).

The obvious consequence will be improved patient adherence and an increased chance of achieving treatment success.

Acknowledgments

The members of “The International Group for the study of Linezolid” are (in alphabetical order): J.W.C. Alffenaar (University of Groningen, University Medical Center Groningen, Dept of Hospital and Clinical Pharmacy, Groningen, the Netherlands), H.A. Anger (New York City Department of Health and Mental Hygiene, Bureau of Tuberculosis Control, New York, NY, USA), J.A. Caminero (MDR-TB Unit, Dept of Pneumology, University General Hospital of Gran Canaria “Dr. Negrin”, Las Palmas de Gran Canaria, Spain and International Union against Tuberculosis and Lung Disease (The Union)), P. Castiglia (Epidemiology and Medical Statistics Unit, Dept of Biomedical Sciences, University of Sassari, Sassari, Italy), S. De Lorenzo (OVV E. Morelli Hospital, Reference Hospital for MDR and HIV-TB, Sondalo, Italy), G. Ferrara (Lung Allergi Kliniken, Karolinska University Hospital, Stockholm, Sweden, and Section of Respiratory Diseases, Dept of Internal Medicine, University of Perugia, Terni, Italy), W.J. Koh (Division of Pulmonary and Critical Care Medicine, Dept of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea), G.F. Schecter (Tuberculosis Control Branch, Division of Communicable Disease Control, Center for Infectious Disease, California Department of Public Health, Richmond, CA, USA), T.S. Shim (Division of Pulmonary and Critical Care Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea), R. Singla (Dept of Tuberculosis and Chest Diseases, Lala Ram Sarup Institute of Tuberculosis and Respiratory Diseases, New Delhi, India), A. Skrahina (Clinical Dept, National Research and Practical Centre for Pulmonology and Tuberculosis, Minsk, Belarus), Z.F. Udwadia (Dept of Pulmonary Medicine, PD Hinduja National Hospital and Medical Research Centre, Veer Savarkar Marg, Mahim, Mumbai, India), M. Villar (General Directorate of Health, Lisbon, Lung Diseases Centre of Venda Nova, Amadora, Portugal), E. Zampogna (World Health Organization Collaborating Centre for Tuberculosis and Lung Diseases, Fondazione S. Maugeri, Care and Research Institute, Tradate, Italy), J.P. Zellweger (TB Clinic, Dept of Ambulatory Care and Community Medicine, University of Lausanne, Lausanne, Switzerland) and A. Zumla (Dept of Infection, Division of Infection and Immunity, Centre for Clinical Microbiology, University College London, London, UK).

Footnotes

  • Conflict of interest: None declared.

  • Received November 26, 2012.
  • Accepted December 24, 2012.
  • ©ERS 2013

References

  1. ↵
    1. Falzon D,
    2. Jaramillo E,
    3. Schünemann HJ,
    4. et al
    . WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011; 38: 516–528.
    OpenUrlAbstract/FREE Full Text
    1. Migliori GB,
    2. Zellweger JP,
    3. Abubakar I,
    4. et al
    . European Union standards for tuberculosis care. Eur Respir J 2012; 39: 807–819.
    OpenUrlAbstract/FREE Full Text
    1. Migliori GB,
    2. Sotgiu G,
    3. Gandhi NR,
    4. et al
    . Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis. Eur Respir J 2013; 42: 169–179.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Skripconoka V,
    2. Danilovits M,
    3. Pehme L,
    4. et al
    . Delamanid improves outcomes and reduces mortality for multidrug-resistant tuberculosis. Eur Respir J 2013; 41: 1393–1400.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Diacon AH,
    2. Dawson R,
    3. von Groote-Bidlingmaier F,
    4. et al
    . 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet 2012; 380: 986–993.
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    1. Cox H,
    2. Ford N
    . Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis. Int J Tuberc Lung Dis 2012; 16: 447–454.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Sotgiu G,
    2. Centis R,
    3. D'Ambrosio L,
    4. et al
    . Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J 2012; 40: 1430–1442.
    OpenUrlAbstract/FREE Full Text
    1. De Lorenzo S,
    2. Alffenaar JW,
    3. Sotgiu G,
    4. et al
    . Efficacy and safety of meropenem–clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB. Eur Respir J 2013; 41: 1386–1392.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Alsaad N,
    2. van Altena R,
    3. Pranger AD,
    4. et al
    . Evaluation of co-trimoxazole in treatment of multidrug-resistant tuberculosis. Eur Respir J 2013 [in press DOI: 10.1183/09031936.00114812].
  7. ↵
    1. Lee M,
    2. Lee J,
    3. Carroll MW,
    4. et al
    . Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med 2012; 367: 1508–1518.
    OpenUrlCrossRefPubMedWeb of Science
View Abstract
PreviousNext
Back to top
View this article with LENS
Vol 42 Issue 1 Table of Contents
European Respiratory Journal: 42 (1)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Linezolid to treat extensively drug-resistant TB: retrospective data are confirmed by experimental evidence
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Linezolid to treat extensively drug-resistant TB: retrospective data are confirmed by experimental evidence
Giovanni Sotgiu, Rosella Centis, Lia D'Ambrosio, Antonio Spanevello, Giovanni Battista Migliori
European Respiratory Journal Jul 2013, 42 (1) 288-290; DOI: 10.1183/09031936.00191712

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Linezolid to treat extensively drug-resistant TB: retrospective data are confirmed by experimental evidence
Giovanni Sotgiu, Rosella Centis, Lia D'Ambrosio, Antonio Spanevello, Giovanni Battista Migliori
European Respiratory Journal Jul 2013, 42 (1) 288-290; DOI: 10.1183/09031936.00191712
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Respiratory infections and tuberculosis
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Drug concentration in lung tissue in MDR-TB
  • Obesity in COPD: the effect of water-based exercise
  • Burden of CAP in Italian general practice
Show more Letters

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society